Europe Tulathromycin Market Size, Share & Trends Analysis Report By Animal Type (Cattle, Swine) and By Country (U.K., Germany, France, Italy, Russia, Nordic, Benelux, Rest of Europe) Forecasts, 2026-2034

Last Updated: September 18, 2026 | Author: Dhanashri Chandgude | Format:

Europe Tulathromycin Market Size

The Europe tulathromycin market size was valued at USD 233.12 million in 2025 and is projected to grow from USD 246.50 million in 2026 to reach USD 385.24 million by 2034, growing at a CAGR of 5.74% during the forecast period 2026–2034.

The patent in the United States, Europe, Canada, and Australia expires in February 2021. Till 2023, the active component tulathromycin is protected in Japan.

Tulathromycin is an antibiotic that works by inhibiting the growth of bacteria. In veterinary medicine, it is typically administered to treat respiratory conditions in cattle and swine. Tulathromycin is covered by Zoetis' intellectual property rights (IPR), and it is marketed as Draxxin.

The high prevalence of BRD and SRD drives the European tulathromycin market. The entry of generic tulathromycin acts as a restraint on this market. On the other hand, a lucrative opportunity for new entrants in generic tulathromycin acts as an opportunity for the tulathromycin market.

Download a Free Sample To learn more about this report.

Animal Type Insights

The market is segmented into Cattle and Swine. Cattle dominated the market and is expected to register a CAGR of 5.4% over the forecast period. Tulathromycin is effective against Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae, the causative agents of swine respiratory disease (SRD).

Europe Tulathromycin Market Size By Segments

Request Customizationto receive a tailored report.

Europe Tulathromycin Market Share By Segments

Speak to an Analystto discuss market opportunities.

Regional Analysis

The Europe tulathromycin market is segmented based on country: Germany, France, the UK, Italy, Spain, and the Rest of Europe.The rest of Europe dominates the country market and is expected to grow at a CAGR of 4.8% during the forecast period.

An innovative triamilide antibacterial drug called tulathromycin has been given European Union approval for use in treating and preventing swine and bovine respiratory diseases. As of 2019, the European region has 143 million pigs and 77 million cattle. Whereas Spain contributed 22% of the pigs and 9% of the cows in the EU, Germany contributed 18% of the pigs and 15% of the cows, France contributed 9% of the pigs and 24% of the cows in the EU, Denmark contributed 9% of the pigs in the EU, the Netherlands contributed another 8%, and Ireland contributed 9% of the cows in the EU.

List of Key and Emerging Players in Europe Tulathromycin Market

Zoetis

Zhejiang Genebest Pharmaceutical

Wisdom Pharmaceutical

Amicogen Biopharm

Hubei Honch Pharmaceutical

Livzon New North River Pharmaceutical

AVF Chemical Industrial

Jiangsu Lingyun Pharmaceutical

Key Industry Developments

October 2025

The European Medicines Agency (EMA) updated the regulatory documentation for Tulaven (tulathromycin), reflecting post-authorisation changes that support the continued availability of the veterinary antibiotic across European markets.

July 2025

Bioveta a.s. expanded its European tulathromycin portfolio after receiving marketing authorisations for its generic Tulathromycin Bioveta 100 mg/ml Solution for Injection, strengthening product availability across multiple EU countries.

January 2025

Bioveta a.s. received additional European marketing authorisations for its Tulathromycin Bioveta 100 mg/ml Solution for Injection, further expanding access to tulathromycin products in Central and Eastern Europe.

Report Scope

Segmentation

By Animal Type 2

Cattle
Swine

Competitive Coverage Zoetis · Zhejiang Genebest Pharmaceutical · Wisdom Pharmaceutical · Amicogen Biopharm · Hubei Honch Pharmaceutical

Research Deliverables Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Customize This Report to Match Your Strategic Objectives

Frequently Asked Questions (FAQs)

The market size is growing at a CAGR of 5.74% from 2026 to 2034.

High prevalence of BRD and SRD is the key driver for the growth of this market.

The key players in this market are The Zoetis,Zhejiang Genebest Pharmaceutical,Wisdom Pharmaceutical,Amicogen Biopharm,Hubei Honch Pharmaceutical Livzon New North River Pharmaceutical,AVF Chemical Industrial,Jiangsu Lingyun Pharmaceutical.

The key restraint in the market is Entry of generic tulathromycin.

About the Author

Dhanashri Chandgude

Senior Research Associate

Dhanashri Chandgude is a healthcare research professional with over four years of experience in market intelligence, specializing in market analysis, secondary research, market estimation, and forecasting across the pharmaceutical, biopharmaceutical, and medical device sectors. She provides actionable insights into market dynamics, competitive intelligence, industry trends, and growth opportunities to support strategic business decision-making.

Her expertise includes assessing market size, growth potential, and revenue opportunities through structured market estimation and forecasting methodologies, including top-down, bottom-up, and epidemiology (EPI)-based approaches. She has hands-on experience analyzing disease epidemiology, treatment landscapes, market trends, competitive scenarios, and industry developments to develop robust market forecasts.